Denny Won

Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.

Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering.

Cooley advised TD Cowen and Cantor, the placement agents on Palvella Therapeutics’ definitive merger agreement with Pieris Pharmaceuticals and concurrent oversubscribed $78.9 million private financing.

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.

Cooley advised the underwriters in Sagimet Biosciences’ $112.5 million follow-on offering. Goldman Sachs, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering. Sagimet Biosciences’ is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid palmitate. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team.